

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person * <u>Bardwell Kathleen</u>			2. Issuer Name and Ticker or Trading Symbol <u>STERIS CORP [ STE ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Sr.V. P. &amp; C.C.O.</u>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>11/02/2015</u>					
<u>C/O 5960 HEISLEY ROAD</u>			4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
(Street)								
<u>MENTOR</u>	<u>OH</u>	<u>44060</u>						
(City)	(State)	(Zip)						

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Shares, No Par Value	11/02/2015		D		15,731 <sup>(1)</sup>	D	(2)	0	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Employee Stock Option (right to buy)	\$22.83	11/02/2015		D			962	(3)	05/21/2019	Common Shares, No Par Value	962	(3)	0	D
Employee Stock Option (right to buy)	\$34.23	11/02/2015		D			1,000	(4)	11/12/2019	Common Shares, No Par Value	1,000	(4)	0	D
Employee Stock Option (right to buy)	\$31.87	11/02/2015		D			4,275	(5)	05/20/2020	Common Shares, No Par Value	4,275	(5)	0	D
Employee Stock Option (right to buy)	\$36.09	11/02/2015		D			4,000	(6)	05/31/2021	Common Shares, No Par Value	4,000	(6)	0	D
Employee Stock Option (right to buy)	\$29.94	11/02/2015		D			3,795	(7)	05/30/2022	Common Shares, No Par Value	3,795	(7)	0	D
Employee Stock Option (right to buy)	\$45.34	11/02/2015		D			5,360	(8)	05/31/2023	Common Shares, No Par Value	5,360	(8)	0	D
Employee Stock Option (right to buy)	\$53.52	11/02/2015		D			7,000	(9)	05/30/2024	Common Shares, No Par Value	7,000	(9)	0	D
Employee Stock Option (right to buy)	\$67.98	11/02/2015		D			10,000	(10)	08/10/2025	Common Shares, No Par Value	10,000	(10)	0	D

**Explanation of Responses:**

1,6805 of these Common Shares are restricted. The restrictions on these Common Shares lapse as follows: 450 on May 31, 2016; 1,155 on May 31, 2016; 450 on May 31, 2017; 750 on May 30, 2016; 750 on May 30, 2017; 750 on May 30, 2018; 625 on May 30, 2016; 625 on May 29, 2017; 625 on May 28, 2018; and 625 on May 28, 2019.

2. Represents shares of STERIS Corporation ("STERIS") disposed of pursuant to merger of a wholly-owned subsidiary of STERIS plc ("New STERIS") with and into STERIS, with STERIS surviving the merger as a wholly-owned subsidiary of New STERIS (the "Merger"), in exchange for ordinary shares of New STERIS, which was consummated simultaneous with and conditioned on New STERIS' acquisition of Synergy Health plc by commencing a "recommended offer" under English law. At the effective time of the Merger, each STERIS common share was cancelled and converted into the right to receive one New STERIS ordinary share.

3. This option is fully vested. This option was assumed by New STERIS in the Merger and converted to an option to purchase 962 ordinary shares of New STERIS for \$22.83 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

4. This option is fully vested. This option was assumed by New STERIS in the Merger and converted to an option to purchase 1,000 ordinary shares of New STERIS for \$34.23 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

5. This option is fully vested. This option was assumed by New STERIS in the Merger and converted to an option to purchase 4,275 ordinary shares of New STERIS for \$31.87 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

6. This option is fully vested. This option was assumed by New STERIS in the Merger and converted to an option to purchase 4,000 ordinary shares of New STERIS for \$36.09 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

7. This option becomes exercisable as follows: 949 on May 30, 2016. This option was assumed by New STERIS in the Merger and converted to an option to purchase 3,795 ordinary shares of New STERIS for \$29.94 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

8. This option becomes exercisable as follows: 1,340 on May 31, 2016 and 1,340 on May 31, 2017. This option was assumed by New STERIS in the Merger and converted to an option to purchase 5,360 ordinary shares of New STERIS for \$45.34 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

9. This option becomes exercisable as follows: 1,750 on May 30, 2016; 1,750 on May 30, 2017 and 1,750 on May 30, 2018. This option was assumed by New STERIS in the Merger and converted to an option to purchase 7,000 ordinary shares of New STERIS for \$53.52 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

10. This option becomes exercisable as follows: 2,500 on May 28, 2016; 2,500 on May 28, 2017; 2,500 on May 28, 2018; and 2,500 on May 28, 2019. This option was assumed by New STERIS in the Merger and converted to an option to purchase 10,000 ordinary shares of New STERIS for \$67.98 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

**Remarks:**

/s/ Dennis P. Patton, Authorized  
Representative under Power of 11/02/2015  
Attorney.

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**